Listing of the Claims:

The following listing of claims replaces all prior versions, and listings, of claims in the application:

Claims 1-23 (canceled)

Claim 24 (previously presented): A method of treating a human patient afflicted with dementia comprising administering a composition comprising a therapeutic unit of Colostrinin in isolated form to the human patient about one or two times per day for a predetermined period of time.

Claim 25 (canceled)

Claim 26 (previously presented): The method according to claim 24 wherein the Colostrinin is non-ovine Colostrinin.

Claim 27 (previously presented): The method according to claim 24, wherein the therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms.

Claim 28 (previously presented): The method according to claim 24 wherein the therapeutic unit of Colostrinin in isolated form is administered to the patient about one or two times each day for a first period of time, followed by a second period of time when

no Colostrinin is administered.

Claim 29 (previously presented): The method according to claim 28 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.

Claim 30 (previously presented): The method according to claim 28 wherein a cycle of administering Colostrinin in isolated form for a first period of time followed by a second period of time when Colostrinin is administered is repeated at least once.

Claims 31-57 (canceled)

Claim 58 (previously presented): A method of treating a human patient afflicted with Alzheimer's Disease comprising administering a composition comprising a therapeutic unit of Colostrinin in isolated form to the human patient about one or two times per day for a predetermined period of time.

Claim 59 (previously presented): The method according to claim 58 wherein the Colostrinin is non-ovine Colostrinin.

Claim 60 (previously presented): The method according to claim 58, wherein the therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms.

Claim 61 (previously presented): The method according to claim 58 wherein the therapeutic unit of Colostrinin in isolated form is administered to the patient about one or two times each day for a first period of time, followed by a second period of time when no Colostrinin is administered.

Claim 62 (previously presented): The method according to claim 61 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.

Claim 63 (previously presented): The method according to claim 61 wherein a cycle of administering Colostrinin in isolated form for a first period of time followed by a second period of time when Colostrinin is administered is repeated at least once.

Claims 64-68 (canceled)

Claim 69 (new): A method of treating a human patient afflicted with dementia comprising administering up to two therapeutic units of Colostrinin in isolated form to the human patient per day, wherein each therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms.

Claim 70 (new): The method according to claim 69 wherein the up to two therapeutic units of Colostrinin in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of Colostrinin are administered to the human patient.

Claim 71 (new): The method according to claim 70 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.

Claim 72 (new): The method according to claim 71 wherein a cycle of administering Colostrinin in isolated form for the first period of time followed by the second period of time when Colostrinin is administered is repeated at least once.

Claim 73 (new): The method according to claim 69 wherein the Colostrinin is formulated for oral administration.

Claim 74 (new): A method of treating a human patient afflicted with Alzheimer's Disease comprising administering up to two therapeutic units of Colostrinin in isolated form to the human patient per day, wherein each therapeutic unit of Colostrinin is in the range of about 25 to 1000 micrograms.

Claim 75 (new): The method according to claim 74 wherein the up to two therapeutic units of Colostrinin in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of Colostrinin are administered to the human patient.

Claim 76 (new): The method according to claim 75 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.

Claim 77 (new): The method according to claim 76 wherein a cycle of administering Colostrinin in isolated form for the first period of time followed by the second period of time when Colostrinin is administered is repeated at least once.

Claim 78 (new): The method according to claim 74 wherein the Colostrinin is formulated for oral administration.

Claim 79 (new): A method of treating a human patient afflicted with dementia comprising administering up to two therapeutic units of a nonapeptide having the amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO: 1) in isolated form to the human patient per day, wherein each therapeutic unit of the nonapeptide is in the range of about 25 to 1000 micrograms.

Claim 80 (new): The method according to claim 79 wherein the up to two therapeutic units of the nonapeptide in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of the nonapeptide are administered to the human patient.

Claim 81 (new): The method according to claim 80 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.

Claim 82 (new): The method according to claim 81 wherein a cycle of administering the nonapeptide in isolated form for the first period of time followed by the second period of time when the nonapeptide is administered is repeated at least once.

Claim 83 (new): The method according to claim 79 wherein the nonapeptide is formulated for oral administration.

Claim 84 (new): A method of treating a human patient afflicted with Alzheimer's Disease comprising administering up to two therapeutic units of a nonapeptide having the amino acid sequence Val-Glu-Ser-Tyr-Val-Pro-Leu-Phe-Pro (SEQ ID NO: 1) in isolated form to the human patient per day, wherein each therapeutic unit of the nonapeptide is in the range of about 25 to 1000 micrograms.

Claim 85 (new): The method according to claim 84 wherein the up to two therapeutic units of the nonapeptide in isolated form are administered to the patient every day or every other day for a first period of time followed by a second period of time when no therapeutic units of the nonapeptide are administered to the human patient.

Claim 86 (new): The method according to claim 85 wherein the first period of time is in the range of about 2 to 4 weeks, and the second period of time is in the range of about 2 to 5 weeks.

Claim 87 (new): The method according to claim 86 wherein a cycle of administering the nonapeptide in isolated form for the first period of time followed by the second period of time when the nonapeptide is administered is repeated at least once.

Claim 88 (new): The method according to claim 84 wherein the nonapeptide is formulated for oral administration.